Renaissance Technologies LLC Decreases Stock Position in Hims & Hers Health, Inc. $HIMS

Renaissance Technologies LLC cut its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 56.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,118,080 shares of the company’s stock after selling 2,699,929 shares during the period. Renaissance Technologies LLC’s holdings in Hims & Hers Health were worth $43,971,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in HIMS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Hims & Hers Health by 23.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after purchasing an additional 78,543 shares in the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health during the first quarter worth $30,000. EverSource Wealth Advisors LLC grew its holdings in shares of Hims & Hers Health by 273.7% during the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after buying an additional 687 shares in the last quarter. Amundi raised its position in shares of Hims & Hers Health by 5.3% in the second quarter. Amundi now owns 10,296 shares of the company’s stock valued at $489,000 after buying an additional 522 shares during the last quarter. Finally, California Public Employees Retirement System raised its position in shares of Hims & Hers Health by 9.5% in the second quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock valued at $16,880,000 after buying an additional 29,471 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on HIMS. Weiss Ratings downgraded shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research note on Tuesday, May 12th. Barclays upped their price objective on shares of Hims & Hers Health from $29.00 to $39.00 and gave the company an “overweight” rating in a research note on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $25.00 price objective on shares of Hims & Hers Health in a report on Tuesday, May 5th. Needham & Company LLC boosted their target price on Hims & Hers Health from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Finally, JPMorgan Chase & Co. dropped their price target on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $31.43.

Insider Buying and Selling

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 23,726 shares of the business’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $35.00, for a total value of $830,410.00. Following the transaction, the insider directly owned 181,861 shares in the company, valued at $6,365,135. The trade was a 11.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 7,573 shares of the stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $30.25, for a total transaction of $229,083.25. Following the completion of the sale, the insider directly owned 11,280 shares of the company’s stock, valued at approximately $341,220. This trade represents a 40.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 83,126 shares of company stock worth $2,711,339 over the last ninety days. 11.76% of the stock is currently owned by insiders.

Hims & Hers Health Stock Up 7.6%

NYSE HIMS opened at $30.23 on Tuesday. The business’s fifty day simple moving average is $30.91 and its 200-day simple moving average is $26.25. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The firm has a market cap of $7.00 billion, a PE ratio of -335.84, a P/E/G ratio of 79.05 and a beta of 2.35. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. During the same period in the prior year, the company posted $0.20 EPS. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.03 earnings per share for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.